Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

By Hishitani Y   Ogata A   Shima Y   Hirano T   Ebina K   Kunugiza Y   Shi K   Narazaki M   Hagihara K   Tomita T   Yoshikawa H   Tanaka T   Kumanogoh A  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 4, 2013-08 ,pp. : 253-259

Informa Healthcare

Access to resources Recommend Favorite

Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis

By  

Current Vascular Pharmacology, Vol. 8, Iss. 2, 2010-01 ,pp. : 285-292

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-α Therapy: Pathophysiology and Clinical Implications

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 5-12

Karger

Access to resources Recommend Favorite

Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α

By Onishi Sachiko   Yoshio Taku   Nagashima Takao   Minota Seiji  

Modern Rheumatology, Vol. 20, Iss. 5, 2010-10 ,pp. : 528-530

Springer Publishing Company

Access to resources Recommend Favorite

Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor α-neutralizing antibody

By Mori Shunsuke   Imamura Fumiya   Kiyofuji Chikage   Sugimoto Mineharu  

Modern Rheumatology, Vol. 16, Iss. 4, 2006-08 ,pp. : 251-255

Springer Publishing Company

Access to resources Recommend Favorite